194 related articles for article (PubMed ID: 34547766)
1. Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia.
Li Z; Lee SHR; Chin WHN; Lu Y; Jiang N; Lim EH; Coustan-Smith E; Chiew KH; Oh BLZ; Koh GS; Chen Z; Kham SKY; Quah TC; Lin HP; Tan AM; Ariffin H; Yang JJ; Yeoh AE
Blood Adv; 2021 Dec; 5(23):5226-5238. PubMed ID: 34547766
[TBL] [Abstract][Full Text] [Related]
2. Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study.
Yeoh AEJ; Lu Y; Chin WHN; Chiew EKH; Lim EH; Li Z; Kham SKY; Chan YH; Abdullah WA; Lin HP; Chan LL; Lam JCM; Tan PL; Quah TC; Tan AM; Ariffin H
J Clin Oncol; 2018 Sep; 36(26):2726-2735. PubMed ID: 30044693
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.
Jeha S; Choi J; Roberts KG; Pei D; Coustan-Smith E; Inaba H; Rubnitz JE; Ribeiro RC; Gruber TA; Raimondi SC; Karol SE; Qu C; Brady SW; Gu Z; Yang JJ; Cheng C; Downing JR; Evans WE; Relling MV; Campana D; Mullighan CG; Pui CH
Blood Cancer Discov; 2021 Jul; 2(4):326-337. PubMed ID: 34250504
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline-Free Protocol for Favorable-Risk Childhood ALL: A Noninferiority Comparison Between Malaysia-Singapore ALL 2003 and ALL 2010 Studies.
Ariffin H; Chiew EKH; Oh BLZ; Lee SHR; Lim EH; Kham SKY; Abdullah WA; Chan LL; Foo KM; Lam JCM; Chan YH; Lin HP; Quah TC; Tan AM; Yeoh AEJ
J Clin Oncol; 2023 Jul; 41(20):3642-3651. PubMed ID: 37276496
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract][Full Text] [Related]
6. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial.
Schwab C; Cranston RE; Ryan SL; Butler E; Winterman E; Hawking Z; Bashton M; Enshaei A; Russell LJ; Kingsbury Z; Peden JF; Barretta E; Murray J; Gibson J; Hinchliffe AC; Bain R; Vora A; Bentley DR; Ross MT; Moorman AV; Harrison CJ
Leukemia; 2023 Mar; 37(3):529-538. PubMed ID: 36550215
[TBL] [Abstract][Full Text] [Related]
7. IKZF1
Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
[TBL] [Abstract][Full Text] [Related]
8. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
[TBL] [Abstract][Full Text] [Related]
9. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch.
Novakova M; Zaliova M; Fiser K; Vakrmanova B; Slamova L; Musilova A; Brüggemann M; Ritgen M; Fronkova E; Kalina T; Stary J; Winkowska L; Svec P; Kolenova A; Stuchly J; Zuna J; Trka J; Hrusak O; Mejstrikova E
Haematologica; 2021 Aug; 106(8):2066-2075. PubMed ID: 32646889
[TBL] [Abstract][Full Text] [Related]
10. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
11. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
Paietta E; Roberts KG; Wang V; Gu Z; Buck GAN; Pei D; Cheng C; Levine RL; Abdel-Wahab O; Cheng Z; Wu G; Qu C; Shi L; Pounds S; Willman CL; Harvey R; Racevskis J; Barinka J; Zhang Y; Dewald GW; Ketterling RP; Alejos D; Lazarus HM; Luger SM; Foroni L; Patel B; Fielding AK; Melnick A; Marks DI; Moorman AV; Wiernik PH; Rowe JM; Tallman MS; Goldstone AH; Mullighan CG; Litzow MR
Blood; 2021 Sep; 138(11):948-958. PubMed ID: 33895809
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Sequencing Allows Comprehensive Genomic Characterization of Pediatric B-Acute Lymphoblastic Leukemia in an Academic Clinical Laboratory.
Hu Z; Kovach AE; Yellapantula V; Ostrow D; Doan A; Ji J; Schmidt RJ; Gu Z; Bhojwani D; Raca G
J Mol Diagn; 2024 Jan; 26(1):49-60. PubMed ID: 37981088
[TBL] [Abstract][Full Text] [Related]
13. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Wang Y; Zeng HM; Zhang LP
Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
[TBL] [Abstract][Full Text] [Related]
14.
Zaliova M; Potuckova E; Hovorkova L; Musilova A; Winkowska L; Fiser K; Stuchly J; Mejstrikova E; Starkova J; Zuna J; Stary J; Trka J
Haematologica; 2019 Jul; 104(7):1407-1416. PubMed ID: 30630977
[No Abstract] [Full Text] [Related]
15. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120.
Fazio G; Bresolin S; Silvestri D; Quadri M; Saitta C; Vendramini E; Buldini B; Palmi C; Bardini M; Grioni A; Rigamonti S; Galbiati M; Mecca S; Savino AM; Peloso A; Tu JW; Bhatia S; Borkhardt A; Micalizzi C; Lo Nigro L; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Te Kronnie G; Biondi A; Cazzaniga G
EBioMedicine; 2022 Sep; 83():104224. PubMed ID: 35985167
[TBL] [Abstract][Full Text] [Related]
16. Successful toxicity reduction during delayed intensification in the non-high-risk arm of Malaysia-Singapore Acute Lymphoblastic Leukaemia 2010 study.
Oh BLZ; Lee SHR; Foo KM; Chiew KH; Seeto ZZL; Chen ZW; Neoh CCC; Liew GSM; Eng JJ; Lam JCM; Chan YH; Quah TC; Tan AM; Yeoh AEJ
Eur J Cancer; 2021 Jan; 142():92-101. PubMed ID: 33246161
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
[TBL] [Abstract][Full Text] [Related]
19. The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
Xue YJ; Wang Y; Jia YP; Zuo YX; Wu J; Lu AD; Zhang LP
Int J Hematol; 2021 Apr; 113(4):547-555. PubMed ID: 33386596
[TBL] [Abstract][Full Text] [Related]
20. Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.
Li J; Dai Y; Wu L; Zhang M; Ouyang W; Huang J; Chen S
Front Med; 2021 Jun; 15(3):347-371. PubMed ID: 33400146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
